Arrowhead Pharmaceuticals, Inc. News

All the news that matters to Arrowhead Pharmaceuticals, Inc.

Arrowhead Reports Positive Phase 1/2a Data For Alzheimer's Candidate ARO-MAPT

www.nasdaq.com | 16:38 Wed 14 Oct 2026

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

finance.yahoo.com | 12:30 Tue 29 Sept 2026

ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near

stocktwits.com | 12:20 Thu 24 Sept 2026

Arrowhead Pharmaceuticals (ARWR) On ARO DIMER PA Data And Whether Undervaluation Still Holds

finance.yahoo.com | 05:18 Sat 19 Sept 2026

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress

www.marketbeat.com | 01:02 Sat 19 Sept 2026

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands